Placebo (matched to Cagrilintide)

DRUG2 trials

Sponsors

Novo Nordisk A/S

Conditions

ObesityOverweightType 2 Diabetes

Phase 1

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

RecruitingNCT07607587

Novo Nordisk A/SObesity, Overweight

Start: 2026-05-29End: 2027-11-19Target: 114Updated: 2026-06-25

Phase 3

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Active, not recruitingNCT07220759

Novo Nordisk A/SObesity, Overweight, Type 2 Diabetes

Start: 2025-11-05End: 2027-06-30Target: 330Updated: 2026-09-04